Related Experiment Video
Updated: Jun 9, 2025
Inducible and Reversible Dominant-negative DN Protein Inhibition
Published on: January 7, 2019
Pharmacologic Blockade of a Pioneer Transcription Factor
Katerina Cermakova1,2, H Courtney Hodges2,3,4
1Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas.
Abstract:
Cancers frequently co-opt lineage-specific transcription factors (TF) utilized in normal development to sustain proliferation. However, the effects of these TFs on tumor development depend considerably on where in the genome they bind. A new article by Taylor and colleagues expands on previously developed diamidine compounds that obstruct the DNA binding sites of the pioneer TF PU.1 (SPI1) in acute myeloid leukemia. Immobilization and sequencing of genomic DNA targeted by these compounds revealed that these inhibitors alter the genomic binding patterns of PU.1. The authors report that their strategy constrains the genomic binding preferences of PU.1, leading to redistribution of PU.1 to promoters and other gene-proximal regions with elevated guanine/cytosine content. In this study, we discuss recent developments for targeting PU.1 in hematologic malignancies. We also explore the shared functional roles of PU.1 and SWI/SNF ATP-dependent chromatin remodeling complexes, which not only work together to sustain the enhancer landscape needed for tumor cell proliferation but also play key roles in nontumor settings.
Insights
New compounds targeting the transcription factor PU.1 (SPI1) alter its genomic binding in acute myeloid leukemia. This strategy redirects PU.1 to promoters, offering a novel approach for hematologic malignancies.
Area of Science:
- Hematology
- Cancer Biology
- Molecular Biology
Background:
- Cancers often hijack developmental transcription factors (TFs) for proliferation.
- The genomic binding sites of TFs like PU.1 (SPI1) critically influence their role in tumor development.
- Pioneer transcription factors play crucial roles in regulating gene expression and chromatin accessibility.
Purpose of the Study:
- To investigate the effects of novel diamidine compounds on the genomic binding patterns of the transcription factor PU.1 (SPI1) in acute myeloid leukemia.
- To explore the therapeutic potential of targeting PU.1 in hematologic malignancies.
- To understand the interplay between PU.1 and SWI/SNF chromatin remodeling complexes in cancer and normal development.
Main Methods:
- Utilized previously developed diamidine compounds to target PU.1 DNA binding sites.
- Employed immobilization and sequencing of genomic DNA to identify PU.1 binding locations.
- Analyzed changes in PU.1 genomic distribution following compound treatment.
Main Results:
- Diamidine compounds successfully altered the genomic binding patterns of PU.1.
- The strategy constrained PU.1's genomic preferences, leading to its redistribution.
- PU.1 was redirected to promoters and gene-proximal regions, particularly those with high guanine/cytosine content.
Conclusions:
- Targeting PU.1 with specific compounds can reprogram its genomic binding in acute myeloid leukemia.
- This approach offers a potential strategy for treating hematologic malignancies by modulating TF function.
- PU.1 and SWI/SNF complexes share functional roles in maintaining the enhancer landscape crucial for tumor proliferation and normal cellular functions.
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
02:36RNA Polymerase II Accessory Proteins
02:16Transcription Factors
02:04Co-activators and Co-repressors
02:23Master Transcription Regulators
01:47Transcription Initiation
The promoters and enhancers and their accessory proteins allow tight regulation of...